BRPI0409926A - saposina c-dops: um agente antitumor - Google Patents

saposina c-dops: um agente antitumor

Info

Publication number
BRPI0409926A
BRPI0409926A BRPI0409926A BRPI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A
Authority
BR
Brazil
Prior art keywords
antitumor agent
saposin
dops
methods
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Xiaoyang Qi
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BRPI0409926A publication Critical patent/BRPI0409926A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SAPOSINA C-DOPS: UM AGENTE ANTITUMOR". A presente invenção refere-se a composições e métodos para o tratamento de indivíduos com distúrbios caracterizados por hiperproliferação de células tais como tumores e cânceres. As composições compreendem agentes que são combinações de saposina C (ou polipeptídeos relacionados com prosaposina e dioleoilfosfatidilserina (ou componentes de folha pequena interna). Este agente antitumor é administrado nos métodos da invenção de acordo com um regime de dosagem. Administração de um agente da invenção resulta em uma resposta terapêutica positiva em um indivíduo com um tumor.
BRPI0409926 2003-04-28 2004-03-17 saposina c-dops: um agente antitumor BRPI0409926A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46616603P 2003-04-28 2003-04-28
US10/801,517 US7834147B2 (en) 2003-04-28 2004-03-16 Saposin C-DOPS: a novel anti-tumor agent
PCT/US2004/008020 WO2004096159A2 (en) 2003-04-28 2004-03-17 Saposin c-dops: a novel anti-tumor agent

Publications (1)

Publication Number Publication Date
BRPI0409926A true BRPI0409926A (pt) 2006-04-25

Family

ID=33423597

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409926 BRPI0409926A (pt) 2003-04-28 2004-03-17 saposina c-dops: um agente antitumor

Country Status (8)

Country Link
US (4) US7834147B2 (pt)
EP (1) EP1635856B1 (pt)
JP (1) JP4762132B2 (pt)
AU (2) AU2004233775C1 (pt)
BR (1) BRPI0409926A (pt)
CA (2) CA2522833C (pt)
ES (1) ES2828094T3 (pt)
WO (1) WO2004096159A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
ES2641272T3 (es) * 2006-04-28 2017-11-08 Children's Hospital Medical Center Composiciones que comprenden proteínas o polipéptidos fusogénicos derivados de la prosaposina para aplicación en sistemas de suministro de fármacos transmembrana
JP5253402B2 (ja) * 2006-10-20 2013-07-31 チルドレンズ ホスピタル メディカル センター 自発的に形成する楕円体の単層リン脂質小胞
AU2013203640B2 (en) * 2007-06-22 2017-04-13 Children's Medical Center Corporation Methods and uses thereof of prosaposin
CA3056116A1 (en) 2007-06-22 2008-12-31 Randolph Watnick Methods and uses thereof of prosaposin
WO2011084685A2 (en) * 2009-12-17 2011-07-14 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9585972B2 (en) 2011-05-09 2017-03-07 Sherry L. Thornton Method for imaging a site of arthritis in an animal
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
EP2745834B1 (en) 2012-12-18 2016-09-28 Jens Frauenfeld Salipro particles
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
LT3043814T (lt) 2013-09-13 2021-02-25 Salipro Biotech AB Antigenas ir jo gamybos būdas
JP6727129B2 (ja) 2014-03-26 2020-07-22 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
AU2017361541A1 (en) 2016-11-21 2019-07-11 Bexion Pharmaceuticals, Inc. A combination therapy including SapC-DOPS for the treatment of pancreatic cancer
EP3697387B1 (en) 2017-10-16 2024-03-06 University of Cincinnati Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme
CN111432816A (zh) 2017-10-16 2020-07-17 辛辛那提大学 用于治疗肿瘤的分次放射与sapc-dops的组合疗法
US10682411B2 (en) * 2018-03-23 2020-06-16 Bexion Pharmaceuticals Inc. Saposin C pharmaceutical compositions and methods of treating cancer
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US12478658B2 (en) * 2020-03-10 2025-11-25 University Of Cincinnati Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer
US20230103407A1 (en) * 2020-03-10 2023-04-06 University Of Cincinnati Materials and methods for the treatment of gaucher disease
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2001A (en) * 1841-03-12 Sawmill
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4552811A (en) 1983-07-26 1985-11-12 Appleton Papers Inc. Capsule manufacture
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
JPS63250323A (ja) * 1987-04-03 1988-10-18 Nichirei:Kk 新規な制癌剤
US4927408A (en) 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
CA2025907A1 (en) * 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
CN1128951A (zh) * 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
DK0726778T3 (da) * 1994-02-08 2001-09-24 Amgen Inc Oral administration af kemisk modificerede proteiner
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE19541284C2 (de) * 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
WO1998033482A1 (en) * 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
AU7795698A (en) 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
ATE348889T1 (de) 2000-02-28 2007-01-15 Bayer Healthcare Ag 27411, eine menschliche phosphatidyl- glycerinphosphate (pgp) synthase
AU2001241769A1 (en) 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. 32621, novel human phospholipid scramblase-like molecules and uses thereof
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
ES2641272T3 (es) * 2006-04-28 2017-11-08 Children's Hospital Medical Center Composiciones que comprenden proteínas o polipéptidos fusogénicos derivados de la prosaposina para aplicación en sistemas de suministro de fármacos transmembrana
JP5253402B2 (ja) 2006-10-20 2013-07-31 チルドレンズ ホスピタル メディカル センター 自発的に形成する楕円体の単層リン脂質小胞
WO2012155147A2 (en) 2011-05-12 2012-11-15 Webtrends, Inc. Graphical-user-interface-based method and system for designing and configuring web-site testing and analysis

Also Published As

Publication number Publication date
EP1635856B1 (en) 2020-08-12
WO2004096159A2 (en) 2004-11-11
CA2911022C (en) 2021-07-20
AU2010200264A1 (en) 2010-02-25
WO2004096159A3 (en) 2005-09-01
AU2010200264B2 (en) 2013-02-14
JP2006524681A (ja) 2006-11-02
US8937156B2 (en) 2015-01-20
JP4762132B2 (ja) 2011-08-31
EP1635856A2 (en) 2006-03-22
AU2004233775C1 (en) 2010-03-18
US20040229799A1 (en) 2004-11-18
CA2911022A1 (en) 2004-11-11
EP1635856A4 (en) 2011-04-06
US20150125497A1 (en) 2015-05-07
US20090269373A1 (en) 2009-10-29
CA2522833A1 (en) 2004-11-11
US20190192623A1 (en) 2019-06-27
ES2828094T3 (es) 2021-05-25
AU2004233775A1 (en) 2004-11-11
AU2004233775B2 (en) 2009-10-22
US7834147B2 (en) 2010-11-16
US10188698B2 (en) 2019-01-29
CA2522833C (en) 2016-01-19

Similar Documents

Publication Publication Date Title
BRPI0409926A (pt) saposina c-dops: um agente antitumor
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
Zheng et al. Synergistic role of thymoquinone on anticancer activity of 5-fluorouracil in triple negative breast cancer cells
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
PT721501E (pt) Composicao farmaceutica que compreende fosfatase ou um seu derivado
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
WO2020061106A3 (en) Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease
Hasan et al. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
Chunhu et al. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells
BRPI0516024A (pt) uso de azd 2171 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
PT1107795E (pt) Tiomolibdato associado com pelo menos um hidrato de carbono e o seu uso para evitar ou tratar doencas caracterizadas por uma vascularizacao tais como cancro degeneracao macular do tipo humido artrite reumatoide
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]